Ovaprene® Phase 3 Trial Shows Promise as Novel Non-Hormonal Contraceptive
Daré Bioscience announced positive interim safety and efficacy results from its Phase 3 clinical trial of Ovaprene, a hormone-free,...
Jon Napitupulu
Evkeeza Approved for HoFH in Infants by Health Canada
Health Canada has expanded the approval of Evkeeza (evinacumab) to include children as young as six months old with...
Brain Fitness Tracker Validated for Aging Independently
A new four-minute online assessment, Freeze Frame, developed by Posit Science, has been validated as a scientific measure of...
Firefly Inks Deal for Precision Neuroscience Research
Firefly Neuroscience is collaborating with Prof. Dr. med. Christian Schaaf of Heidelberg University Hospital on a study investigating the...
Amtagvi® Shows 49% Response Rate in Advanced Melanoma Patients
Iovance Biotherapeutics announced positive real-world data for its commercially available melanoma treatment, Amtagvi (lifileucel). A study of 41 patients...
Bria-IMT™ Shows Survival Advantage in Metastatic Breast Cancer
BriaCell Therapeutics Corp. announced positive Phase 2 survival data for its lead immunotherapy candidate, Bria-IMT, combined with an immune...
Capricor Provides Deramiocel-BLA Update for Duchenne Muscular Dystrophy
Capricor Therapeutics received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for Deramiocel,...
Italfarmaco Presents New Cardiac Data for Givinostat
Italfarmaco presented new cardiac data for givinostat, its histone deacetylase (HDAC) inhibitor, at the 2025 European Paediatric Neurology Society...
Setmelanotide & Bivamelagon Data at ENDO 2025
Rhythm Pharmaceuticals presented data from its clinical programs for acquired hypothalamic obesity at the Endocrine Society’s Annual Meeting (ENDO...
KIF18A Therapies: FDA & EMA Approvals, Trials, and Indications
KIF18A, a mitotic kinesin motor protein overexpressed in cancers like ovarian and triple-negative breast cancers, is emerging as a...